Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Julia Benckert"'
Autor:
Sylvia Saalfeld, Robert Kreher, Georg Hille, Uli Niemann, Mattes Hinnerichs, Osman Öcal, Kerstin Schütte, Christoph J. Zech, Christian Loewe, Otto vanDelden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Irene Bargellini, Roberto Iezzi, Thomas Berg, Heinz J. Klümpen, Julia Benckert, Antonio Gasbarrini, Holger Amthauer, Bruno Sangro, Peter Malfertheiner, Bernhard Preim, Jens Ricke, Max Seidensticker, Maciej Pech, Alexey Surov
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 14, Iss 5, Pp 2301-2309 (2023)
Abstract Background Parameters of body composition have prognostic potential in patients with oncologic diseases. The aim of the present study was to analyse the prognostic potential of radiomics‐based parameters of the skeletal musculature and adi
Externí odkaz:
https://doaj.org/article/4b85fbe9c89740f49ba92613b317aa10
Autor:
Can G. Leineweber, Miriam Rabehl, Anne Pietzner, Nadine Rohwer, Michael Rothe, Maciej Pech, Bruno Sangro, Rohini Sharma, Chris Verslype, Bristi Basu, Christian Sengel, Jens Ricke, Nils Helge Schebb, Karsten-H. Weylandt, Julia Benckert
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/b9260c68d14a43f7a3628074ecc8465c
Autor:
Can G. Leineweber, Miriam Rabehl, Anne Pietzner, Nadine Rohwer, Michael Rothe, Maciej Pech, Bruno Sangro, Rohini Sharma, Chris Verslype, Bristi Basu, Christian Sengel, Jens Ricke, Nils Helge Schebb, Karsten-H. Weylandt, Julia Benckert
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Hepatocellular carcinoma (HCC) is a leading cause of cancer death, and medical treatment options are limited. The multikinase inhibitor sorafenib was the first approved drug widely used for systemic therapy in advanced HCC. Sorafenib might affect pol
Externí odkaz:
https://doaj.org/article/630cda002caf4e259f38d949754a2b84
Autor:
Osman Öcal, Juozas Kupčinskas, Egidijus Morkunas, Holger Amthauer, Kerstin Schütte, Peter Malfertheiner, Heinz Josef Klümpen, Christian Sengel, Julia Benckert, Ricarda Seidensticker, Bruno Sangro, Moritz Wildgruber, Maciej Pech, Peter Bartenstein, Jens Ricke, Max Seidensticker
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Background To confirm the prognostic value of previously published baseline interleukin 6 (IL6) and IL8 cutoff values in survival and liver dysfunction in patients with advanced HCC undergoing 90Y radioembolization. Methods A total of 83 pat
Externí odkaz:
https://doaj.org/article/b832054cf65348e4be321b5fb11a5a14
Autor:
Marianna Alunni-Fabbroni, Kerstin Rönsch, Thomas Huber, Clemens C. Cyran, Max Seidensticker, Julia Mayerle, Maciej Pech, Bristi Basu, Chris Verslype, Julia Benckert, Peter Malfertheiner, Jens Ricke
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-15 (2019)
Abstract Background Liquid biopsy based on cell-free DNA circulating in plasma has shown solid results as a non-invasive biomarker. In the present study we evaluated the utility of circulating free DNA (cfDNA) and the sub-type tumor DNA (ctDNA) in he
Externí odkaz:
https://doaj.org/article/c1825c1ef0f2494784138247015bb147
Autor:
Osman Öcal, Kerstin Schütte, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Irene Bargellini, Roberto Iezzi, Alexander Philipp, Thomas Berg, Heinz J. Klümpen, Julia Benckert, Maciej Pech, Antonio Gasbarrini, Holger Amthauer, Peter Bartenstein, Bruno Sangro, Peter Malfertheiner, Jens Ricke, Max Seidensticker
Publikováno v:
European journal of nuclear medicine and molecular imaging, 49(13), 4716-4726. Springer Verlag
Öcal, O, Schütte, K, Zech, C J, Loewe, C, van Delden, O, Vandecaveye, V, Verslype, C, Gebauer, B, Sengel, C, Bargellini, I, Iezzi, R, Philipp, A, Berg, T, Klümpen, H J, Benckert, J, Pech, M, Gasbarrini, A, Amthauer, H, Bartenstein, P, Sangro, B, Malfertheiner, P, Ricke, J & Seidensticker, M 2022, ' Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 13, pp. 4716-4726 . https://doi.org/10.1007/s00259-022-05920-8
European Journal of Nuclear Medicine and Molecular Imaging, 49(13), 4716-4726. Springer Verlag
Öcal, O, Schütte, K, Zech, C J, Loewe, C, van Delden, O, Vandecaveye, V, Verslype, C, Gebauer, B, Sengel, C, Bargellini, I, Iezzi, R, Philipp, A, Berg, T, Klümpen, H J, Benckert, J, Pech, M, Gasbarrini, A, Amthauer, H, Bartenstein, P, Sangro, B, Malfertheiner, P, Ricke, J & Seidensticker, M 2022, ' Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 13, pp. 4716-4726 . https://doi.org/10.1007/s00259-022-05920-8
European Journal of Nuclear Medicine and Molecular Imaging, 49(13), 4716-4726. Springer Verlag
Purpose To compare the treatment response and progression-free survival (PFS) in advanced hepatocellular carcinoma (HCC) patients who received sorafenib treatment either alone or combined with radioembolization (RE). Methods Follow-up images of the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a8562555a121697a7e2558c87ce9e89
https://doi.org/10.1007/s00259-022-05920-8
https://doi.org/10.1007/s00259-022-05920-8
Autor:
Jens Ricke, Han Chong Toh, Pierce Kah Hoe Chow, Antonio Gasbarrini, Christiane Kuhl, Bruno Sangro, Julia Benckert, Maciej Pech, Regina Schinner, Moritz Wildgruber, Peter Malfertheiner, Elif Öcal, Marianna Alunni-Fabbroni, Timothy Wai Ho Shuen
Purpose:SORAMIC is a randomized controlled trial in patients with advanced hepatocellular carcinoma (HCC) undergoing sorafenib ± selective internal radiation therapy (SIRT). We investigated the value of extracellular vesicle (EV)-based proteomics fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3208829c464a681a4982a0bfec94bd0d
https://doi.org/10.1158/1078-0432.c.6532479
https://doi.org/10.1158/1078-0432.c.6532479
Autor:
Jens Ricke, Han Chong Toh, Pierce Kah Hoe Chow, Antonio Gasbarrini, Christiane Kuhl, Bruno Sangro, Julia Benckert, Maciej Pech, Regina Schinner, Moritz Wildgruber, Peter Malfertheiner, Elif Öcal, Marianna Alunni-Fabbroni, Timothy Wai Ho Shuen
Supplementary Data from Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::721eeef5883fb5de6903c7f21f2ee212
https://doi.org/10.1158/1078-0432.22487268
https://doi.org/10.1158/1078-0432.22487268
Autor:
Imke Schatka, Hans V. Jochens, Julian M. M. Rogasch, Thula C. Walter-Rittel, Uwe Pelzer, Julia Benckert, Josefine Graef, Felix W. Feldhaus, Bernhard Gebauer, Holger Amthauer
Publikováno v:
Cancers; Volume 14; Issue 21; Pages: 5324
Radioembolization (RE) is a viable therapy option in patients with intrahepatic cholangiocarcinoma (ICC). This study delineates a prognostic score regarding overall survival (OS) after RE using routine pre-therapeutic parameters. A retrospective anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e47d56544cf931368c989a11c9f8812b
https://pubmed.ncbi.nlm.nih.gov/36358743
https://pubmed.ncbi.nlm.nih.gov/36358743
Autor:
Tobias Müller, Julia Benckert, Heiner Wedemeyer, Armin Koch, Armin Papkalla, Sven Pischke, Ansgar W. Lohse, Markus Cornberg, Maria von Karpowitz, Svenja Hardtke, Eike Steinmann, Daniel Todt, Felix Piecha, Michael P. Manns, Patrick Behrendt
Publikováno v:
Journal of Hepatology. 73:696-699
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25f19629f6d68a6c4687b9d013d47ed2
https://doi.org/10.1016/j.jhep.2020.05.020
https://doi.org/10.1016/j.jhep.2020.05.020